Yasushi Nagata
Yasushi Nagata has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Daisuke Kawahara
Department of Radiation Oncology, Graduate School of Biomedical Health Sciences, Hiroshima University, Hiroshima, Japan
5 shared publications - Nobuki Imano
Department of Radiation Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
4 shared publications - Shuichi Ozawa
Department of Radiation Oncology Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
4 shared publications Akito Saito
Department of Radiation Oncology Institute of Biomedical & Health Sciences Hiroshima University Hiroshima Japan
3 shared publicationsTomoki Kimura
Japanese Radiation Oncology Study Group (JROSG) Lung and Mediastinal Cancer Committee , 2-4-11 Fukagawa, Koto-ku, Tokyo, 135-0033
3 shared publications- Yuji Murakami
Department of Radiation Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan
3 shared publications
Latest Publications
- Open Access
- 5 February 2026
- Published by Oxford University Press (OUP) in Journal of Radiation Research
- Vol. 67 (2) , 228-235
Definitive radiotherapy practices for small-cell lung cancer in Japan: a national survey (JROSG 23-3)
This survey examined the real-world practice of radiotherapy for small-cell lung cancer (SCLC) in Japan, focusing on treatment strategies for limited-disease SCLC (LD-SCLC) and extensive-disease SCLC (ED-SCLC). This study aimed to identify inter-institutional differences, optimize treatment strategies and explore opportunities for standardization. A questionnaire was distributed to members of the Japanese Radiation Oncology Study Group, and responses were collected from 15 December 2023 to 14 March 2024. Responses to 11 questions specifically related to SCLC treatment strategies were analyzed. Among the 112 institutions, 38.3% did not set an upper age limit for concurrent chemoradiotherapy in LD-SCLC, whereas 31.3% set the limit at 80 years. The most commonly used chemotherapy regimen was cisplatin plus etoposide (79.5%), and the predominant radiotherapy fractionation schedule was twice-daily 45 Gy in 30 fractions (97.3%). Elective nodal irradiation (ENI) was ommited in 30.4% of institutions, while 17.9% reported performing ENI in all cases. Intensity-modulated radiation therapy (IMRT) was introduced in 71.4% of institutions, with D50% as the most frequently used dose-prescription method (47.5%). After achieving complete response, 16.1% of institutions routinely perform prophylactic cranial irradiation (PCI) in all patients. Hippocampus-sparing PCI was not widely used at the time of the survey (13.3%). In conclusion, this Japanese nationwide survey highlighted the SCLC treatment patterns and differences compared with non-small lung cancer (NSCLC). ENI omissions and IMRT have become increasingly adopted for SCLC, whereas clinical target volume margin definitions show some variation compared with NSCLC. Regular surveys are essential to monitor the evolution of treatment strategies.
- 5 February 2026
- Published by Oxford University Press (OUP) in Journal of Radiation Research
- Vol. 67 (2) , 228-235
Open AccessDefinitive radiotherapy practices for small-cell lung cancer in Japan: a national survey (JROSG 23-3)
This survey examined the real-world practice of radiotherapy for small-cell lung cancer (SCLC) in Japan, focusing on treatment strategies for limited-disease SCLC (LD-SCLC) and extensive-disease SCLC (ED-SCLC). This study aimed to identify inter-institutional differences, optimize treatment strategies and explore opportunities for standardization. A questionnaire was distributed to members of the Japanese Radiation Oncology Study Group, and responses were collected from 15 December 2023 to 14 March 2024. Responses to 11 questions specifically related to SCLC treatment strategies were analyzed. Among the 112 institutions, 38.3% did not set an upper age limit for concurrent chemoradiotherapy in LD-SCLC, whereas 31.3% set the limit at 80 years. The most commonly used chemotherapy regimen was cisplatin plus etoposide (79.5%), and the predominant radiotherapy fractionation schedule was twice-daily 45 Gy in 30 fractions (97.3%). Elective nodal irradiation (ENI) was ommited in 30.4% of institutions, while 17.9% reported performing ENI in all cases. Intensity-modulated radiation therapy (IMRT) was introduced in 71.4% of institutions, with D50% as the most frequently used dose-prescription method (47.5%). After achieving complete response, 16.1% of institutions routinely perform prophylactic cranial irradiation (PCI) in all patients. Hippocampus-sparing PCI was not widely used at the time of the survey (13.3%). In conclusion, this Japanese nationwide survey highlighted the SCLC treatment patterns and differences compared with non-small lung cancer (NSCLC). ENI omissions and IMRT have become increasingly adopted for SCLC, whereas clinical target volume margin definitions show some variation compared with NSCLC. Regular surveys are essential to monitor the evolution of treatment strategies.
- Open Access
- 5 November 2025
- Published by Oxford University Press (OUP) in Journal of Radiation Research
- Vol. 66 (6) , 689-698
National survey on definitive radiotherapy practices for locally advanced non-small cell lung cancer in Japan: JROSG 23–3
This survey was conducted to examine the real-world practice of definitive chemoradiotherapy (CRT) for locally advanced non-small cell lung cancer (LA-NSCLC) in Japan, aiming to standardize treatment, reduce inter-institutional disparities and identify areas for future research. A questionnaire was sent to members of the Japanese Radiation Oncology Study Group through a mailing list, with responses collected between December 15, 2023, and March 14, 2024. Responses from 112 institutions revealed that 81.2% either did not set general upper age limits or established limits at 80 years or older for definitive CRT in LA-NSCLC. The most common absolute contraindications were active interstitial pneumonia (60.7%) and contralateral hilar lymph node metastasis (42.0%). Relative contraindications involved dose-volume indices of the normal lung (70.5%). The most commonly adopted dose-volume indices were lung V20Gy < 30%, lung V5Gy < 60% and mean lung dose <20 Gy, while no definite indices were established for heart V50Gy and mean heart dose in half of the institutions. Additionally, 88.4% of institutions reported using IMRT for LA-NSCLC. Involved-field radiotherapy (IFRT) was adopted regardless of institutional size, and institutions with higher IMRT usage for LA-NSCLC also had higher IFRT adoption rates. In conclusion, this nationwide survey revealed the expanded use of definitive CRT and a growing emphasis on reducing lung dose to mitigate pulmonary toxicities, facilitated by advancements in IMRT and IFRT. Regularly conducting these surveys is essential to monitor evolving treatment strategies.
- 5 November 2025
- Published by Oxford University Press (OUP) in Journal of Radiation Research
- Vol. 66 (6) , 689-698
Open AccessNational survey on definitive radiotherapy practices for locally advanced non-small cell lung cancer in Japan: JROSG 23–3
This survey was conducted to examine the real-world practice of definitive chemoradiotherapy (CRT) for locally advanced non-small cell lung cancer (LA-NSCLC) in Japan, aiming to standardize treatment, reduce inter-institutional disparities and identify areas for future research. A questionnaire was sent to members of the Japanese Radiation Oncology Study Group through a mailing list, with responses collected between December 15, 2023, and March 14, 2024. Responses from 112 institutions revealed that 81.2% either did not set general upper age limits or established limits at 80 years or older for definitive CRT in LA-NSCLC. The most common absolute contraindications were active interstitial pneumonia (60.7%) and contralateral hilar lymph node metastasis (42.0%). Relative contraindications involved dose-volume indices of the normal lung (70.5%). The most commonly adopted dose-volume indices were lung V20Gy < 30%, lung V5Gy < 60% and mean lung dose <20 Gy, while no definite indices were established for heart V50Gy and mean heart dose in half of the institutions. Additionally, 88.4% of institutions reported using IMRT for LA-NSCLC. Involved-field radiotherapy (IFRT) was adopted regardless of institutional size, and institutions with higher IMRT usage for LA-NSCLC also had higher IFRT adoption rates. In conclusion, this nationwide survey revealed the expanded use of definitive CRT and a growing emphasis on reducing lung dose to mitigate pulmonary toxicities, facilitated by advancements in IMRT and IFRT. Regularly conducting these surveys is essential to monitor evolving treatment strategies.
- 18 September 2025
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 55 (12) , 1316-1325
Stereotactic body radiotherapy for lung cancer: a review
Stereotactic body radiation therapy (SBRT) is a radiotherapy technique that has been widely adopted in clinical settings for lung cancer treatment since the 1990s. In this study, we reviewed the medical history and current standard techniques of SBRT. Previous clinical studies on lung cancer, including those conducted by Japan Clinical Oncology Group, have demonstrated high local control rates with acceptable toxicities. Current indications for SBRT include expanded inoperable peripheral lung cancer to include operable, central, or oligometastatic lung cancer. We also reviewed the past and ongoing international clinical trials.
- 18 September 2025
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 55 (12) , 1316-1325
Stereotactic body radiotherapy for lung cancer: a review
Stereotactic body radiation therapy (SBRT) is a radiotherapy technique that has been widely adopted in clinical settings for lung cancer treatment since the 1990s. In this study, we reviewed the medical history and current standard techniques of SBRT. Previous clinical studies on lung cancer, including those conducted by Japan Clinical Oncology Group, have demonstrated high local control rates with acceptable toxicities. Current indications for SBRT include expanded inoperable peripheral lung cancer to include operable, central, or oligometastatic lung cancer. We also reviewed the past and ongoing international clinical trials.
- 26 November 2024
- Published by IOP Publishing in Biomedical Physics & Engineering Express
- Vol. 11 (1) , 015019
Dose compensation for decreased biological effective dose due to intrafractional interruption during radiotherapy: integration with a commercial treatment planning system
Objective. While the biological effective dose (BED) has been used to estimate the damage to tumor cells in radiotherapy, BED does not consider intrafractional interruption (IFI) occurring during irradiation. We aim to develop a framework to evaluate the decrease in BED [ Δ BED ] and to create a plan compensating for the decrease by IFI. Approach. Δ BED was calculated using a model based on the microdosimetric kinetic model (MKM) for four brain tumor cases treated using a volumetric-modulated arc therapy. Four biologically compensated plans (BCPs) were created in the treatment planning system by a single-time optimization using a base plan considering Δ BED created in in-house software and optimization objectives for the original clinically delivered plan to achieve a homogeneous BED distribution within the planning target volume (PTV). The BED-volume histogram was evaluated for non-compensated plan and BCP with different timepoint of interruption, a percentage of gantry rotation angle (GRA) before interruption in planned GRA, η and duration of interruption τ . Characteristics of the dose accumulation were analyzed for different collimator angle sets, Plan A (10°, 85°) and Plan B (45° and 315°), for the first case. Main Results. Hot spots in the Δ BED distribution for η = 25%, 50%, and 75% were observed at superior-and-interior ends, central region, and peripheral region in PTV, respectively. These behaviors could be understood by characteristics of the MKM-based model producing maximum Δ BED at 50% of the dose accumulation. Δ BED 50 % ranged 4.5%–6.6%, 5.0%–7.3%, and 5.3%–7.7% for τ = 60, 90, and 120 min, respectively. Plan A showed fast dose accumulation at superior and inferior edges while slow on peripheries in the lateral dose profile. Plan B showed more homogeneous PD distributions than Plan A during irradiation. Significance. The developed framework successfully evaluated and compensated for the decreased BED distribution.
- 26 November 2024
- Published by IOP Publishing in Biomedical Physics & Engineering Express
- Vol. 11 (1) , 015019
Dose compensation for decreased biological effective dose due to intrafractional interruption during radiotherapy: integration with a commercial treatment planning system
Objective. While the biological effective dose (BED) has been used to estimate the damage to tumor cells in radiotherapy, BED does not consider intrafractional interruption (IFI) occurring during irradiation. We aim to develop a framework to evaluate the decrease in BED [ Δ BED ] and to create a plan compensating for the decrease by IFI. Approach. Δ BED was calculated using a model based on the microdosimetric kinetic model (MKM) for four brain tumor cases treated using a volumetric-modulated arc therapy. Four biologically compensated plans (BCPs) were created in the treatment planning system by a single-time optimization using a base plan considering Δ BED created in in-house software and optimization objectives for the original clinically delivered plan to achieve a homogeneous BED distribution within the planning target volume (PTV). The BED-volume histogram was evaluated for non-compensated plan and BCP with different timepoint of interruption, a percentage of gantry rotation angle (GRA) before interruption in planned GRA, η and duration of interruption τ . Characteristics of the dose accumulation were analyzed for different collimator angle sets, Plan A (10°, 85°) and Plan B (45° and 315°), for the first case. Main Results. Hot spots in the Δ BED distribution for η = 25%, 50%, and 75% were observed at superior-and-interior ends, central region, and peripheral region in PTV, respectively. These behaviors could be understood by characteristics of the MKM-based model producing maximum Δ BED at 50% of the dose accumulation. Δ BED 50 % ranged 4.5%–6.6%, 5.0%–7.3%, and 5.3%–7.7% for τ = 60, 90, and 120 min, respectively. Plan A showed fast dose accumulation at superior and inferior edges while slow on peripheries in the lateral dose profile. Plan B showed more homogeneous PD distributions than Plan A during irradiation. Significance. The developed framework successfully evaluated and compensated for the decreased BED distribution.
- Open Access
- 12 December 2023
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 97 (1153) , 142-149
Dosiomics for intensity-modulated radiotherapy in patients with prostate cancer: survival analysis stratified by baseline prostate-specific antigen and Gleason grade group in a 2-institutional retrospective study
This study evaluated the prognostic impact of the quality of dose distribution using dosiomics in patients with prostate cancer, stratified by pretreatment prostate-specific antigen (PSA) levels and Gleason grade (GG) group. A total of 721 patients (Japanese Foundation for Cancer Research [JFCR] cohort: N = 489 and Tokyo Radiation Oncology Clinic [TROC] cohort: N = 232) with localized prostate cancer treated by intensity-modulated radiation therapy were enrolled. Two predictive dosiomic features for biochemical recurrence (BCR) were selected and patients were divided into certain groups stratified by pretreatment PSA levels and GG. Freedom from biochemical failure (FFBF) was estimated using the Kaplan–Meier method based on each dosiomic feature and univariate discrimination was evaluated using the log-rank test. As an exploratory analysis, a dosiomics hazard (DH) score was developed and its prognostic power for BCR was examined. The dosiomic feature extracted from planning target volume (PTV) significantly distinguished the high- and low-risk groups in patients with PSA levels >10 ng/mL (7-year FFBF: 86.7% vs 76.1%, P < .01), GG 4 (92.2% vs 76.9%, P < .01), and GG 5 (83.1% vs 77.8%, P = .04). The DH score showed significant association with BCR (hazard score: 2.04; 95% confidence interval: 1.38-3.01; P < .001). The quality of planned dose distribution on PTV may affect the prognosis of patients with poor prognostic factors, such as PSA levels >10 ng/mL and higher GGs. The effects of planned dose distribution on prognosis differ depending on the patient’s clinical background.
- 12 December 2023
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 97 (1153) , 142-149
Open AccessDosiomics for intensity-modulated radiotherapy in patients with prostate cancer: survival analysis stratified by baseline prostate-specific antigen and Gleason grade group in a 2-institutional retrospective study
This study evaluated the prognostic impact of the quality of dose distribution using dosiomics in patients with prostate cancer, stratified by pretreatment prostate-specific antigen (PSA) levels and Gleason grade (GG) group. A total of 721 patients (Japanese Foundation for Cancer Research [JFCR] cohort: N = 489 and Tokyo Radiation Oncology Clinic [TROC] cohort: N = 232) with localized prostate cancer treated by intensity-modulated radiation therapy were enrolled. Two predictive dosiomic features for biochemical recurrence (BCR) were selected and patients were divided into certain groups stratified by pretreatment PSA levels and GG. Freedom from biochemical failure (FFBF) was estimated using the Kaplan–Meier method based on each dosiomic feature and univariate discrimination was evaluated using the log-rank test. As an exploratory analysis, a dosiomics hazard (DH) score was developed and its prognostic power for BCR was examined. The dosiomic feature extracted from planning target volume (PTV) significantly distinguished the high- and low-risk groups in patients with PSA levels >10 ng/mL (7-year FFBF: 86.7% vs 76.1%, P < .01), GG 4 (92.2% vs 76.9%, P < .01), and GG 5 (83.1% vs 77.8%, P = .04). The DH score showed significant association with BCR (hazard score: 2.04; 95% confidence interval: 1.38-3.01; P < .001). The quality of planned dose distribution on PTV may affect the prognosis of patients with poor prognostic factors, such as PSA levels >10 ng/mL and higher GGs. The effects of planned dose distribution on prognosis differ depending on the patient’s clinical background.
- Open Access
- 30 December 2021
- Published by VM Media Group sp. z o.o in Reports of Practical Oncology and Radiotherapy
- Vol. 26 (6) , 1035-1044
Impact on liver position under breath-hold by computed tomography contrast agents in stereotactic body radiotherapy of liver cancer
Background: We investigated variations in liver position relative to the vertebral bone for liver cancer treated with stereotactic body radiation therapy under expiratory phase breath-hold (BH) for treatment with contrast-enhanced-computed tomography (CECT), non-CECT, and cone-beam computed tomography (CBCT). Materials and methods: Seventeen consecutive patients using a contrast enhancement (CE) agent for the CT simulation session for this retrospective study were selected. The first computed tomography (CT) scan without the use of CE agent in the expiratory phase was used for treatment planning (pCT). The remaining three CT scans without a CE agent under expiratory phase BH were acquired successively without repositioning to evaluate the intra-fraction variation in liver position. Furthermore, a three-phase CT scan (arterial, portal, and late phases) accompanied by a CE agent under expiratory phase BH was acquired for target delineation. CBCT scans without the use of a CE agent under expiratory phase BH were acquired for treatment. Inter-fractional variations (non-CECT or CECT) in liver position were measured using the difference between CBCT and pCT or each 3 phase CECT images, respectively. Results: The average ± standard deviations for intrafractional, non-CECT interfractional variations, and CECT interfractional variations were 1.0 ± 1.3, 2.5 ± 2.6, and 6.4 ± 6.4 mm, respectively, in the craniocaudal (CC) direction. Intra- and inter-fractional variations in liver position were relatively small for non-CECT. However, significant inter-fractional liver position variations in CECT were observed in the expiratory phase BH. The position of the liver should be carefully considered when applying CECT images for image-guided radiotherapy. Background: We investigated variations in liver position relative to the vertebral bone for liver cancer treated with stereotactic body radiation therapy under expiratory phase breath-hold (BH) for treatment with contrast-enhanced-computed tomography (CECT), non-CECT, and cone-beam computed tomography (CBCT). Materials and methods: Seventeen consecutive patients using a contrast enhancement (CE) agent for the CT simulation session for this retrospective study were selected. The first computed tomography (CT) scan without the use of CE agent in the expiratory phase was used for treatment planning (pCT). The remaining three CT scans without a CE agent under expiratory phase BH were acquired successively without repositioning to evaluate the intra-fraction variation in liver position. Furthermore, a three-phase CT scan (arterial, portal, and late phases) accompanied by a CE agent under expiratory phase BH was acquired for target delineation. CBCT scans without the use of a CE agent under expiratory phase BH were acquired for treatment. Inter-fractional variations (non-CECT or CECT) in liver position were measured using the difference between CBCT and pCT or each 3 phase CECT images, respectively. Results: The average ± standard deviations for intrafractional, non-CECT interfractional variations, and CECT interfractional variations were 1.0 ± 1.3, 2.5 ± 2.6, and 6.4 ± 6.4 mm, respectively, in the craniocaudal (CC) direction. Intra- and inter-fractional variations in liver position were relatively small for non-CECT. However, significant inter-fractional liver position variations in CECT were observed in the expiratory phase BH. The position of the liver should be carefully considered when applying CECT images for image-guided radiotherapy.
- 30 December 2021
- Published by VM Media Group sp. z o.o in Reports of Practical Oncology and Radiotherapy
- Vol. 26 (6) , 1035-1044
Open AccessImpact on liver position under breath-hold by computed tomography contrast agents in stereotactic body radiotherapy of liver cancer
Background: We investigated variations in liver position relative to the vertebral bone for liver cancer treated with stereotactic body radiation therapy under expiratory phase breath-hold (BH) for treatment with contrast-enhanced-computed tomography (CECT), non-CECT, and cone-beam computed tomography (CBCT). Materials and methods: Seventeen consecutive patients using a contrast enhancement (CE) agent for the CT simulation session for this retrospective study were selected. The first computed tomography (CT) scan without the use of CE agent in the expiratory phase was used for treatment planning (pCT). The remaining three CT scans without a CE agent under expiratory phase BH were acquired successively without repositioning to evaluate the intra-fraction variation in liver position. Furthermore, a three-phase CT scan (arterial, portal, and late phases) accompanied by a CE agent under expiratory phase BH was acquired for target delineation. CBCT scans without the use of a CE agent under expiratory phase BH were acquired for treatment. Inter-fractional variations (non-CECT or CECT) in liver position were measured using the difference between CBCT and pCT or each 3 phase CECT images, respectively. Results: The average ± standard deviations for intrafractional, non-CECT interfractional variations, and CECT interfractional variations were 1.0 ± 1.3, 2.5 ± 2.6, and 6.4 ± 6.4 mm, respectively, in the craniocaudal (CC) direction. Intra- and inter-fractional variations in liver position were relatively small for non-CECT. However, significant inter-fractional liver position variations in CECT were observed in the expiratory phase BH. The position of the liver should be carefully considered when applying CECT images for image-guided radiotherapy. Background: We investigated variations in liver position relative to the vertebral bone for liver cancer treated with stereotactic body radiation therapy under expiratory phase breath-hold (BH) for treatment with contrast-enhanced-computed tomography (CECT), non-CECT, and cone-beam computed tomography (CBCT). Materials and methods: Seventeen consecutive patients using a contrast enhancement (CE) agent for the CT simulation session for this retrospective study were selected. The first computed tomography (CT) scan without the use of CE agent in the expiratory phase was used for treatment planning (pCT). The remaining three CT scans without a CE agent under expiratory phase BH were acquired successively without repositioning to evaluate the intra-fraction variation in liver position. Furthermore, a three-phase CT scan (arterial, portal, and late phases) accompanied by a CE agent under expiratory phase BH was acquired for target delineation. CBCT scans without the use of a CE agent under expiratory phase BH were acquired for treatment. Inter-fractional variations (non-CECT or CECT) in liver position were measured using the difference between CBCT and pCT or each 3 phase CECT images, respectively. Results: The average ± standard deviations for intrafractional, non-CECT interfractional variations, and CECT interfractional variations were 1.0 ± 1.3, 2.5 ± 2.6, and 6.4 ± 6.4 mm, respectively, in the craniocaudal (CC) direction. Intra- and inter-fractional variations in liver position were relatively small for non-CECT. However, significant inter-fractional liver position variations in CECT were observed in the expiratory phase BH. The position of the liver should be carefully considered when applying CECT images for image-guided radiotherapy.
- Open Access
- 16 December 2020
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 22 (1) , 165-173
Formulation of objective indices to quantify machine failure risk analysis for interruptions in radiotherapy
Objectives: To evaluate the effect of interruption in radiotherapy due to machine failure in patients and medical institutions using machine failure risk analysis (MFRA).Material and methods: The risk of machine failure during treatment is assigned to three scores (biological effect, B; occurrence, O; and cost of labor and repair parts, C) for each type of machine failure. The biological patient risk (BPR) and the economic institution risk (EIR) are calculated as the product of and () and and (), respectively. The MFRA is performed in two linear accelerators (linacs).Result: The multileaf collimator (MLC) fault has the highest BPR and second highest EIR. In particular, TrueBeam has a higher BPR and EIR for MLC failures. The total EIR in TrueBeam was significantly higher than that in Clinac iX. The minor interlock had the second highest BPR, whereas a smaller EIR. Meanwhile, the EIR for the LaserGuard fault was the highest, and that for the monitor chamber fault was the second highest. These machine failures occurred in TrueBeam. The BPR and EIR should be evaluated for each linac. Further, the sensitivity of the BPR, it decreased with higher and α/β values. No relative difference is observed in the BPR for each machine failure when and α/β were varied.Conclusion: The risk faced by patients and institutions in machine failure may be reduced using MFRA.Advances in knowledge: For clinical radiotherapy, interruption can occur from unscheduled downtime with machine failures. Interruption causes sublethal damage repair. The current study evaluated the effect of interruption in radiotherapy owing to machine failure on patients and medical institutions using a new method, that is, machine failure risk analysis.
- 16 December 2020
- Published by Wiley in Journal of Applied Clinical Medical Physics
- Vol. 22 (1) , 165-173
Open AccessFormulation of objective indices to quantify machine failure risk analysis for interruptions in radiotherapy
Objectives: To evaluate the effect of interruption in radiotherapy due to machine failure in patients and medical institutions using machine failure risk analysis (MFRA).Material and methods: The risk of machine failure during treatment is assigned to three scores (biological effect, B; occurrence, O; and cost of labor and repair parts, C) for each type of machine failure. The biological patient risk (BPR) and the economic institution risk (EIR) are calculated as the product of and () and and (), respectively. The MFRA is performed in two linear accelerators (linacs).Result: The multileaf collimator (MLC) fault has the highest BPR and second highest EIR. In particular, TrueBeam has a higher BPR and EIR for MLC failures. The total EIR in TrueBeam was significantly higher than that in Clinac iX. The minor interlock had the second highest BPR, whereas a smaller EIR. Meanwhile, the EIR for the LaserGuard fault was the highest, and that for the monitor chamber fault was the second highest. These machine failures occurred in TrueBeam. The BPR and EIR should be evaluated for each linac. Further, the sensitivity of the BPR, it decreased with higher and α/β values. No relative difference is observed in the BPR for each machine failure when and α/β were varied.Conclusion: The risk faced by patients and institutions in machine failure may be reduced using MFRA.Advances in knowledge: For clinical radiotherapy, interruption can occur from unscheduled downtime with machine failures. Interruption causes sublethal damage repair. The current study evaluated the effect of interruption in radiotherapy owing to machine failure on patients and medical institutions using a new method, that is, machine failure risk analysis.
- Open Access
- 1 May 2020
- Published by VM Media Group sp. z o.o in Reports of Practical Oncology and Radiotherapy
- Vol. 25 (3) , 376-381
Characterization of robust optimization for VMAT plan for liver cancer
We investigated the feasibility of robust optimization for volumetric modulated arc therapy (VMAT) stereotactic body radiation therapy (SBRT) for liver cancer in comparison with planning target volume (PTV)-based optimized plans. Treatment plan quality, robustness, complexity, and accuracy of dose delivery were assessed. Ten liver cancer patients were selected for this study. PTV-based optimized plans with an 8-mm PTV margin and robust optimized plans with an 8-mm setup uncertainty were generated. Plan perturbed doses were evaluated using a setup error of 8 mm in all directions from the isocenter. The dosimetric comparison parameters were clinical target volume (CTV) doses (D98%, D50%, and D2%), liver doses, and monitor unit (MU). Plan complexity was evaluated using the modulation complexity score for VMAT (MCSv). There was no significant difference between the two optimizations with respect to CTV doses and MUs. Robust optimized plans had a higher liver dose than did PTV-based optimized plans. Plan perturbed dose evaluations showed that doses to the CTV for the robust optimized plans had small variations. Robust optimized plans were less complex than PTV-based optimized plans. Robust optimized plans had statistically significant fewer leaf position errors than did PTV-based optimized plans. Comparison of treatment plan quality, robustness, and plan complexity of both optimizations showed that robust optimization could be feasibile for VMAT of liver cancer.
- 1 May 2020
- Published by VM Media Group sp. z o.o in Reports of Practical Oncology and Radiotherapy
- Vol. 25 (3) , 376-381
Open AccessCharacterization of robust optimization for VMAT plan for liver cancer
We investigated the feasibility of robust optimization for volumetric modulated arc therapy (VMAT) stereotactic body radiation therapy (SBRT) for liver cancer in comparison with planning target volume (PTV)-based optimized plans. Treatment plan quality, robustness, complexity, and accuracy of dose delivery were assessed. Ten liver cancer patients were selected for this study. PTV-based optimized plans with an 8-mm PTV margin and robust optimized plans with an 8-mm setup uncertainty were generated. Plan perturbed doses were evaluated using a setup error of 8 mm in all directions from the isocenter. The dosimetric comparison parameters were clinical target volume (CTV) doses (D98%, D50%, and D2%), liver doses, and monitor unit (MU). Plan complexity was evaluated using the modulation complexity score for VMAT (MCSv). There was no significant difference between the two optimizations with respect to CTV doses and MUs. Robust optimized plans had a higher liver dose than did PTV-based optimized plans. Plan perturbed dose evaluations showed that doses to the CTV for the robust optimized plans had small variations. Robust optimized plans were less complex than PTV-based optimized plans. Robust optimized plans had statistically significant fewer leaf position errors than did PTV-based optimized plans. Comparison of treatment plan quality, robustness, and plan complexity of both optimizations showed that robust optimization could be feasibile for VMAT of liver cancer.
- Open Access
- 9 September 2019
- Published by Wiley in Cancer Medicine
- Vol. 8 (15) , 6519-6527
Effect of bevacizumab against cystic components of brain tumors
Background: Bevacizumab improves symptoms via reducing the peritumoral edema and/or normalizing blood brain barrier, and occasionally via reducing the tumor size. However, the effect against active cystic components has not been documented yet.Materials and Methods: Between 2008 and 2018, 139 patients with primary or metastatic brain tumors were treated with bevacizumab (BEV) in our institution. The images and symptoms before and after administration of BEV were examined, and changes in size of cysts were evaluated as follows: CR (complete disappearance), PR (reduction by ≥50%), MR (reduction by ≥25%), SD (size change P = .0055) and at best response timing (mean 76.3% vs 32.8%, P = .0050). Patients with cysts showed significant improvement in symptoms after the treatment with BEV compared to patients without cysts (P = .0033). However, response rate was not different between patients with or without cysts. Overall survival after starting BEV was not different between glioblastoma patients with or without cysts.Conclusion: Bevacizumab is effective against progressively increasing cysts. Although cysts reduction effect and tumor response and/or overall survival are independent, BEV may be effective in patients who are symptomatic due to cyst enlargement.
- 9 September 2019
- Published by Wiley in Cancer Medicine
- Vol. 8 (15) , 6519-6527
Open AccessEffect of bevacizumab against cystic components of brain tumors
Background: Bevacizumab improves symptoms via reducing the peritumoral edema and/or normalizing blood brain barrier, and occasionally via reducing the tumor size. However, the effect against active cystic components has not been documented yet.Materials and Methods: Between 2008 and 2018, 139 patients with primary or metastatic brain tumors were treated with bevacizumab (BEV) in our institution. The images and symptoms before and after administration of BEV were examined, and changes in size of cysts were evaluated as follows: CR (complete disappearance), PR (reduction by ≥50%), MR (reduction by ≥25%), SD (size change P = .0055) and at best response timing (mean 76.3% vs 32.8%, P = .0050). Patients with cysts showed significant improvement in symptoms after the treatment with BEV compared to patients without cysts (P = .0033). However, response rate was not different between patients with or without cysts. Overall survival after starting BEV was not different between glioblastoma patients with or without cysts.Conclusion: Bevacizumab is effective against progressively increasing cysts. Although cysts reduction effect and tumor response and/or overall survival are independent, BEV may be effective in patients who are symptomatic due to cyst enlargement.
- Open Access
- 1 October 2018
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 91 (1090) , 20180396
Automatic contrast medium extraction system using electron density data with dual-energy CT
Objectives:The purpose of the current study is to create a contrast medium extraction method using raw-data-based electron density (rED) and CT number from dual-energy CT (DECT) for automatic delineation of the contrast region.Methods:A CT-ED phantom containing tissue-equivalent inserts and an acrylic phantom with an iodinated contrast medium were scanned by DECT. The contrast medium extraction system was created using Python. The accuracy of the contrast medium extraction was evaluated by measuring the diameter in terms of the full width at half maximum (FWHM) and the ratio of the volume (ROV).Results:Mean-2SD CT numbers and the difference of the CT numbers (DCT) of the contrast medium at 0–130 mg ml−1 contrast medium concentration and the bone materials were more than −33 HU and −20 HU, respectively. In the correlation of rED and CT number, the gradient with the contrast medium phantom was greater than that with the CT-ED phantom. The accuracy of the contrast medium at 80 kV/135 kV and 100 kV/135 kV tub...
- 1 October 2018
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 91 (1090) , 20180396
Open AccessAutomatic contrast medium extraction system using electron density data with dual-energy CT
Objectives:The purpose of the current study is to create a contrast medium extraction method using raw-data-based electron density (rED) and CT number from dual-energy CT (DECT) for automatic delineation of the contrast region.Methods:A CT-ED phantom containing tissue-equivalent inserts and an acrylic phantom with an iodinated contrast medium were scanned by DECT. The contrast medium extraction system was created using Python. The accuracy of the contrast medium extraction was evaluated by measuring the diameter in terms of the full width at half maximum (FWHM) and the ratio of the volume (ROV).Results:Mean-2SD CT numbers and the difference of the CT numbers (DCT) of the contrast medium at 0–130 mg ml−1 contrast medium concentration and the bone materials were more than −33 HU and −20 HU, respectively. In the correlation of rED and CT number, the gradient with the contrast medium phantom was greater than that with the CT-ED phantom. The accuracy of the contrast medium at 80 kV/135 kV and 100 kV/135 kV tub...